Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension
New England Journal of Medicine · 02.02.2023 · 388 (5) · 395-405
DOI: 10.1056/nejmoa2213169 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift New England Journal of Medicine, erschienen am 02.02.2023. Verfasst von Mason W Freeman und 11 weiteren Autor:innen. Beteiligte Einrichtung: From CinCor Pharma (M.W.F., Y.-D.H., W.M., C.P.) and Brigham and Women's Hospital, Harvard Medical School (D.L.B.) - both in Boston; CinRx Pharma (M.…. Hauptthemen laut MEDLINE: Antihypertensive Agents, Cytochrome P-450 CYP11B2, Hypertension. Die Arbeit wurde bisher 403-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Medical Research Council, CinCor Pharma, Inc..
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From CinCor Pharma (M.W.F., Y.-D.H., W.M., C.P.) and Brigham and Women's Hospital, Harvard Medical School (D.L.B.) - both in Boston; CinRx Pharma (M.P., J.I., B.M.) and Medpace (N.A., A.S.) - both in Cincinnati; and the…
ORCID-Profile: Deepak L Bhatt, Morris J Brown
Förderung
- Medical Research Council
- CinCor Pharma, Inc.
Zitieren
APA
Freeman, M. W., Halvorsen, Y. D., Marshall, W., Pater, M., Isaacsohn, J., Pearce, C., Murphy, B., Alp, N., Srivastava, A., Bhatt, D. L., Brown, M. J., & BrigHTN Investigators (2023). Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. New England Journal of Medicine, 388(5), 395-405. https://doi.org/10.1056/nejmoa2213169
Vancouver
Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. New England Journal of Medicine. 2023;388(5):395-405. doi:10.1056/nejmoa2213169
BibTeX
@article{Freeman2023,
author = {Freeman, Mason W and Halvorsen, Yuan-Di and Marshall, William and Pater, Mackenzie and Isaacsohn, Jon and Pearce, Catherine and Murphy, Brian and Alp, Nicholas and Srivastava, Ajay and Bhatt, Deepak L and Brown, Morris J and BrigHTN Investigators, BrigHTN Investigators},
title = {Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension},
journal = {New England Journal of Medicine},
year = {2023},
volume = {388},
number = {5},
pages = {395--405},
doi = {10.1056/nejmoa2213169}
}
EUVIMED